AccessPath is a novel, affordable, slide-free pathology system that helps surgeons determine if they have completely removed tumors during surgery. Photo via Getty Images

The Biden-Harris administration is deploying $150 million as a part of its Cancer Moonshot initiative, and a research team led by Rice University is getting a slice of that pie.

AccessPath is a novel, affordable, slide-free pathology system that helps surgeons determine if they have completely removed tumors during surgery. Rebecca Richards-Kortum, a Rice bioengineering professor and director of the Rice360 Institute for Global Health Technologies, is the lead PI on the project that is receiving up to $18 million over five years from the Advanced Research Projects Agency for Health (ARPA-H).

“Because of its low cost, high speed, and automated analysis, we believe AccessPath can revolutionize real-time surgical guidance, greatly expanding the range of hospitals able to provide accurate intraoperative tumor margin assessment and improving outcomes for all cancer surgery patients,” Richards-Kortum says in a news release.

The project is focused on two types of cancer, breast and head and neck cancer, and Ashok Veeraraghavan, chair of Rice’s Department of Electrical and Computer Engineering and a professor of electrical and computer engineering and computer science, is a co-PI and Tomasz Tkaczyk, a professor of bioengineering and electrical and computer engineering at Rice, is also a collaborator on the project.

AccessPath is addressing the challenge surgeons face of identifying the margin where tumor tissue ends and health tissue begins when removing tumors. The project not only hopes to provide a more exact solution but do so in an affordable way.

“Precise margin assessment is key to the oncologic success of any cancer operation,” adds Dr. Ana Paula Refinetti, an associate professor in the Department of Breast Surgical Oncology at The University of Texas MD Anderson Cancer Center and one of the lead surgeons PIs on the project. “The development of a new low-cost technology that enables immediate margin assessment could transform the landscape of surgical oncology — particularly in low-resource settings, reducing the number of repeat interventions, lowering cancer care costs and improving patient outcomes.”

The project optimizing margin identification with a fast-acting, high-resolution microscope, effective fluorescent stains for dying tumor margins, and artificial intelligence algorithms.

AccessPath is a collaboration between Rice and MD Anderson Cancer Center, other awardees in the grant include the University of Texas Health School of Dentistry, Duke University, Carnegie Mellon University and 3rd Stone Design.

“AccessPath is exactly the kind of life-changing research and health care innovation we are proud to produce at Rice, where we’re committed to addressing and solving the world’s most pressing medical issues,” Ramamoorthy Ramesh, Rice’s executive vice president for research, says in the release. “Partnering with MD Anderson on this vital work underscores the importance of such ongoing collaborations with our neighbors in the world’s largest medical center. I am thrilled for Rebecca and her team; it’s teamwork that makes discoveries like these possible.”

Rebecca Richards-Kortum, a Rice bioengineering professor and director of the Rice360 Institute for Global Health Technologies, is the lead PI on the project. Photo by Jeff Fitlow/Rice University

Researchers from Rice University and the University of Texas have teamed up for semiconductor microsystem innovation. Photo via Getty Images

Houston semiconductor researchers join DARPA-funded Texas team

teaming up

A team led by the University of Texas at Austin and partnered with Rice University was awarded $840 million to develop “the next generation of high-performing semiconductor microsystems" for the U.S. Department of Defense.

The Defense Advanced Research Projects Agency (DARPA) selected UT’s Texas Institute for Electronics (TIE) semiconductor consortium to establish a national open access R&D and prototyping fabrication facility.

The facility hopes to enable the DOD to create higher performance, lower power, lightweight, and compact defense systems. The technology could apply to radar, satellite imaging, unmanned aerial vehicles, or other systems, and ultimately will assist with national security and global military leadership. As a member of DARPA’s Next Generation Microelectronics Manufacturing (NGMM) team, Rice’s contributions are key.

Executive vice president for research Ramamoorthy Ramesh and the Rice researchers will focus on technologies for improving computing efficiency. In a Rice press release, Ramesh notes the need to enhance “energy-efficient computing” which highlights Rice’s qualifications to contribute to the solution.

New microsystem designs will be enabled by 3D heterogeneous integration (3DHI)semi, which is a semiconductor fabrication technology that integrates diverse materials and components into microsystems via precision assembly technologies.

Kepler Computing, is a member of the NGMM team and utilizes ferroelectrics to develop energy-efficient approaches in computer memory and logic, and was co-founded by Ramesh. Other Rice researchers include:

  • Lane Martin, director of the Rice Advanced Materials Institute
  • Ashok Veeraraghavan, chair of electrical and computer engineering
  • Pulickel Ajayan, the Benjamin M. and Mary Greenwood Anderson Professor of Engineering and founding chair of the materials science and nanoengineering department
  • Kaiyuan Yang, associate professor of electrical and computer engineering
  • Guha Balakrishnan, assistant professor of electrical and computer engineering

“Given the rapid growth of machine learning AI applications, there is a pressing need to fundamentally rethink current computing methodologies to advance the next generation of microelectronics,” Ramesh says in a news release. ”Rice University boasts world-class researchers with exceptional expertise in computer and electrical engineering poised to bolster this critical federally funded initiative.”

Overall, the project represents a total investment of $1.4 billion. The $840 million award from DARPA is a return on the Texas Legislature’s $552 million investment in TIE. TIE has funded the update of two UT fabrication facilities.

“TIE is tapping into the semiconductor talent available in Texas and nationally to build an outstanding team of semiconductor technologists and executives that can create this national center of excellence in 3DHI microsystems,” S.V. Sreenivasan, TIE founder and chief technology officer and UT professor of mechanical engineering adds.

------

This article originally ran on EnergyCapital.

At Houston event, the Department of Energy’s Advanced Research Projects Agency-Energy announced $100 million in cleantech funding. Photos by Jeff Fitlow/Rice University

National agency announces $100M in funding for energy advancement at Houston event

seeing green

Rice University played host to the first-of-its-kind event from the Department of Energy’s Advanced Research Projects Agency-Energy, or ARPA-E, earlier this month in which the governmental agency announced $100 million in funding for its SCALEUP program.

Dubbed “ARPA-E on the Road: Houston,” the event welcomed more than 100 energy innovators to the Hudspeth Auditorium in Rice’s Anderson-Clarke Center on June 8. Evelyn Wang, director of ARPA-E, announced the funding, which represents the third installment from the agency for its program SCALEUP, or Seeding Critical Advances for Leading Energy technologies with Untapped Potential, which supports the commercialization of clean energy technology.

The funding is awarded to previous ARPA-E awardees with a "viable road to market" and "ability to attract private sector investments," according to a statement from the Department of Energy. Previous funding was granted in 2019 and 2021.

"ARPA-E’s SCALEUP program has successfully demonstrated what can happen when technical experts are empowered with the commercialization support to develop a strong pathway to market” Wang said. “I’m excited that we are building on the success of this effort with the third installment of SCALEUP, and I look forward to what the third cohort of teams accomplish.”

Rice Vice President for Research Ramamoorthy Ramesh also spoke at the event on how Rice is working to make Houston a leader in energy innovation. Joe Zhou, CEO of Houston-based Quidnet Energy, also spoke on a panel about how ARPA-E funding benefited his company along with Oregon-based Onboard Dynamics’s CEO Rita Hansen and Massachusetts-based Quaise Energy’s CEO Carlos Araque.

Attendees were able to ask questions to Wang and ARPA-E program directors about the agency’s funding approach and other topics at the event.

Houston energy innovators have benefited from programs like SCALEUP.

Quidnet Energy received $10 million in funding from ARPA-E as part of its SCALEUP program in 2022. The company's technology can store renewable energy for long periods of time in large quantities.

In January, Houston-based Zeta Energy also announced that it has secured funding from ARPA-E. The $4 million in funding came from the agency's Electric Vehicles for American Low-Carbon Living, or EVs4ALL, program. Zeta Energy is known for its lithium sulfur batteries

------

This article originally ran on EnergyCapital. 

Here are two of the latest updates on new appointments from two Houston organizations. Photos courtesy

2 Houston organizations announce strategic appointments across finance and research

short stories

Two Houston innovators have new roles they're excited about this summer. From new academia to bitcoin, here's who's moving and shaking in Houston innovation.

Rice University names vice president for research

Ramamoorthy Ramesh joins Rice to lead research. Photo via Rice.edu

Rice University named Ramamoorthy Ramesh, a condensed matter physicist and materials scientist with more than 25 years of experience, as vice president for research. He most recently chaired energy technology and taught physics at the University of California, Berkeley. He is expected to start his new position on August 15. He follows Yousif Shamoo, who served as in the position for eight years, and Doug Natelson, has acted as interim since June.

“Ramesh comes to Rice with a distinguished research career and a wealth of experience and knowledge in various types of research enterprises,” says newly inducted Rice President Reginald DesRoches. “I am confident he will be a transformational leader who can strengthen Rice’s reputation as a center of increasingly impactful and broad-based interdisciplinary research that retains a deep commitment to pedagogy and the student experience.”

In addition to his extensive leadership at Berkeley, Ramesh was the founding director of the U.S. Department of Energy SunShot Initiative, deputy director of science and technology at Oak Ridge National Laboratory, and associate laboratory director at the Lawrence Berkeley National Laboratory, per a news Rice release.

“Building upon its rapidly rising research portfolio, Rice has the potential to further strengthen and expand its engagement with public and private funding agencies and be the science and technology beacon for the world,” he says in the release. “I look forward to helping make that happen and to engaging on behalf of the university at various state, national and international fora of relevance to the Rice research enterprise.”

Bitcoin expert joins Houston financial firm

Lisa Hough has a new title. Image courtesy of LevelField

Houston-based LevelField Financial has named Lisa Hough as the company’s head of business development. The financial services firm focuses on uniting digital assets and traditional banking services onto one platform. Hough, with her background in bitcoin and energy trading, will focus on expanding LevelField's market presence and report to Gene A. Grant, II, founder and CEO of the company.

“Lisa is the perfect addition to LevelField's veteran banking and financial service executive team. Her experience will meet our clients’ wants and needs, which are well-managed and regulated investment products that blend established and emerging digital assets,” says Grant in a news release. "Lisa's ability to connect with clients will enable them to rapidly build a well-informed perspective on digital assets.”

Hough has a decade of experience in natural gas trading and risk management at energy trading organizations, including Vastar Resources, Enron, and PG&E National Energy Group, and is a frequent speaker at global finance and energy conferences.

“My passion is to educate and connect all people to bitcoin because it is the only form of property that can be held by every human on earth, regardless of property rights,” she says in the release.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.